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!Abstract 
 
 The purpose of this thesis was to determine if the amount of the protein 
Orthodenticle homeobox 2 (Otx2) is reduced in individuals with schizophrenia. Otx2 is a 
transcription factor that plays an essential role in the development and maintenance of a 
specific class of GABAergic interneurons that express the protein parvalbumin (PV+ 
GABAergic interneurons). In addition, Otx2 participates in the development and 
maintenance of perineuronal nets. Perineuronal nets are important extracellular matrix 
structures that encompass PV+ GABAergic interneurons and facilitate their proper 
functioning (Beurdeley, 2012). It is speculated that perineuronal net structural 
abnormalities can lead to impaired PV+ GABAergic interneuron function and these 
impairments contribute to the manifestation of the condition schizophrenia (Berretta et 
al., 2015). Because Otx2 is needed for both healthy PV+ GABAergic interneurons and 
functional perineuronal nets, we postulated that insufficient levels of Otx2 in the 
amygdala might contribute to impaired GABAergic neurotransmission as exhibited in 
individuals with schizophrenia. Interestingly, PV+ GABAergic interneurons that require 
Otx2 do not produce Otx2. Recently, it was shown in mouse models that Otx2 is made in 
the choroid plexus, released into the cerebral spinal fluid and carried to cortical areas 
where it becomes available to be used by neurons (Spattazza et al., 2013). Similarly, in 
human postmortem samples, we observed the presence of Otx2 in the choroid plexus 
(Pantazopoulos et al., Manuscript in Preparation). Furthermore, we observed a novel 
phenomenon in human samples; Otx2 was found in vesicles in the cerebral spinal fluid 
!and in the amygdala samples. We hypothesized that PV+ GABAergic interneurons 
located in the amygdala obtained Otx2 from the choroid plexus by delivery in vesicles via 
the cerebral spinal fluid. Based on this observation and building on current scientific 
understanding of schizophrenia, we proposed that there would be fewer vesicles in the 
amygdala samples donated by individuals with schizophrenia compared to samples 
donated by healthy controls. To test this hypothesis, the number of vesicles that contained 
Otx2 in amygdala samples donated by individuals diagnosed with schizophrenia (n=15) 
was compared to the number of vesicles that contained Otx2 in amygdala samples 
donated by healthy control donors (n=15). The results showed that there was not a 
significant decrease in the number of vesicles that contained Otx2 in amygdala samples 
donated by individuals with schizophrenia compared to samples donated by healthy 
controls (p-value > 0.05). However, an enzyme linked immunosorbent assay (ELISA) 
was performed to measure the amount of Otx2 inside vesicles and a significant decrease 
in the amount of Otx2 was observed in cerebral spinal fluid samples donated by 
individuals with schizophrenia (n=11) compared to healthy controls (n=15), (p-value < 
0.05). In conclusion, this thesis work honed in on three major ideas. First, the method of 
delivery of Otx2 to neurons in the amygdala appeared to be via vesicles filled with Otx2, 
which originated in the choroid plexus.  Second, there was not a decrease in the number 
of vesicles that contained Otx2 in samples from individuals with schizophrenia. Finally, 
preliminary experiments that measured Otx2 protein concentration inside the vesicles 
indicated that the amount of Otx2 contained in the vesicles was reduced in samples 
donated by individuals with schizophrenia compared to healthy controls. These finding 
!are potential first steps in the development of a bioassay for the molecular 
characterization of the condition of schizophrenia. 
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Chapter I 
Introduction 
 
Schizophrenia is a chronic and debilitating neuropsychiatric condition that has 
affected individuals throughout history. Although the term schizophrenia was only coined 
in the 19th century, individuals with “psychotic-like conditions” have been described in 
various written sources as early as 1,000 B.C. (Evans, Mcgrath, & Milins, 2003; 
Weinberger, 2010).  
For example, writings from the Old Testament indicate that King Saul 
experienced paranoia, along with visual and auditory hallucinations. Anecdotal accounts 
of his symptoms have lead researchers to postulate that King Saul was afflicted with a 
condition akin to schizophrenia (Heinrichs, 2003 & Weinberger, 2010). 
Furthermore, individuals with “schizophrenic-like psychosis” were described in 
Greece during the 10th century B.C. as being mad. It was generally believed that the 
cause of madness was an infliction by the gods, rather than a psychological disorder with 
a biological origin. Afflicted individuals were sent to temples in locations such as 
Aesculapius for various treatments (Hinshaw, 2007).  
During the age of Pericleas, Hippocrates (460-377 B.C.) advanced the 
understanding of mental illness from a medical perspective. He was one of the first 
individuals to propose that mental illnesses were rooted in biological origins (First, 
Frances, & Pincus, 2004).  
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Hippocrates came to this conclusion through detailed observations of individuals 
with pathological traits such as melancholia, hysteria, seizures, and mania. It is 
speculated that Hippocrates used the term “mania” in reference to what are now 
identified as the positive symptoms of schizophrenia (Angst & Marneros, 2001; 
Weinberger, 2011).                                                        
Many years later, during the 18th century psychotic symptoms were more clearly 
delineated and the term schizophrenia was coined. Two clinicians, Emil Kraepelin (1856-
1926) and Eugene Bleuler (1857-1939) are widely credited with these advancements. 
 In 1919, Kraepelin published Dementia Praecox and Paraphrenia; this was a 
comprehensive description of the various and diverse behavioral abnormalities exhibited 
by individuals with psychosis. It is important to note that Kraepelin studied patients in a 
clinical setting, who were considered very ill (Kraepelin, 1971). 
  Based on his clinical observations, Dementia Praecox and Paraphrenia provided a 
conceptual framework for what later would be identified as the condition of 
schizophrenia. The term dementia praecox was used to indicate that this psychological 
illness manifests in adolescence (praecox is the Latin term for “early”) (Kraepelin, 1971; 
First et al., 2004; Weinberger, 2010). 
 Interestingly, Kraepelin observed that there were two disparate groups of 
individuals with psychosis. He differentiated the two groups by long-term clinical 
outcome. The first group was composed of individuals who experienced episodes of 
psychosis, but eventually went into remission. Kraepelin diagnosed the individuals in this 
group with manic-depression, today known as bipolar disorder. 
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 The second group was composed of individuals with chronic psychosis, who 
unfortunately, experienced severe and permanent cognitive deterioration. The individuals 
in this group were diagnosed with dementia praecox (Kraepelin, 1971; Weinberger, 
2010).  
Although Kraepelin argued that both delusions and hallucinations were symptoms 
of schizophrenia, he believed that negative symptoms and chronic cognitive deterioration 
were key identifying features of the disease (Kraepelin, 1971, Jablensky, 2010; 
Weinberger, 2010). According to Kraepelin, negative symptoms included alogia, 
avolition, anhedonia, blunted affect and deficits in selective attention (Weinberger, 2010). 
Like Kraepelin, Bleuler theorized that schizophrenia had key fundamental and 
secondary symptoms. He also believed that negative symptoms were key features of the 
disease (First et al., 2004). Bleuler described negative symptoms as deficits in 
associations, affect deregulation, autism, and ambivalence (Weinberger, 2010). However, 
Bleuler theorized that delusions and hallucinations were not defining characteristics of 
schizophrenia because they also occurred in other illnesses, such as bipolar disorder 
(Rosenzweig, Breedlove, & Watson, 2005).  
In contrast to Kraepelin, Bleuler conceptualized that schizophrenia was not 
always associated with severe and permanent cognitive deterioration. This may be 
because Bleuler identified a subset of individuals with schizophrenia who were not as ill 
as the individuals that Kraepelin studied. He proposed that the condition of 
schizophrenia might have diverse biological origins, which in turn determine the severity 
of the affected individual’s psychological wellbeing (Bleuler, 1950; Ashok, Baugh, & 
Yeragani, 2012). 
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Eventually, Bleuler coined the term schizophrenia, which replaced the term 
dementia praecox from clinical use. The term schizophrenia was chosen to indicate that 
affected individuals experienced a fragmentation of thoughts or a “splitting of the mind” 
(Jablensky, 2010). The German word “schizien” means split and “phren” is the Greek 
word for mind (Bleuler, 1950; Weinberger, 2010; Ashok et al., 2012).  
Today, the condition of schizophrenia is identified by negative, positive and 
disorganized symptoms. These symptoms cause the individual to experience profound 
disruptions in processing emotions, cognitive tasks, and social interactions. It is estimated 
that worldwide, between one and three percent of the population suffers from 
schizophrenia. Schizophrenia is categorized under the Schizophrenia Spectrum and Other 
Psychotic Disorders section in the DSM-5 (DSM-5, 2013). 
The diagnostic criteria for an individual to be identified as having schizophrenia 
necessitates that the individual experiences two or more of the following symptoms: 
delusions, hallucinations, disorganized speech, grossly disorganized or catatonic 
behavior, or negative symptoms. The individual must be symptomatic for a significant 
portion of time over the course of one month (DSM-5, 2013). 
The World Health Organization reports that schizophrenia is one of the top ten 
illnesses that contribute to the global burden of disease. The global burden of disease is a 
measure of mortality and disability caused by a given illness (Murray & Lopez, 1996; 
Weinberger, 2010; Tsuang, 2011).  
Unfortunately, the World Health Organization estimates that half of individuals 
affected with schizophrenia do not receive appropriate care. This is of concern for many 
reasons, one of which is that individuals with schizophrenia are vulnerable to self-harm; 
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the suicide rate for individuals with schizophrenia is five times higher than that of non-
affected individuals (Hor & Taylor, 2010). 
In addition to individual and familial suffering, there are socio-economic burdens 
associated with schizophrenia, which are measured by direct and indirect costs. Direct 
costs are an estimate of the amount of money spent on one’s medical treatment; this 
includes the cost of doctor’s visits, hospital stays and the cost of medication, as well as 
any criminal justice expenses an affected individual may have accrued. Indirect costs are 
the estimated dollar amount of lost productivity and contribution to society by the 
affected individual. In 2002, in the United States, direct and indirect costs of 
schizophrenia management were estimated at 62.7 billion dollars (McEvoy, 2007). 
The scientific community currently believes that an individual is likely to develop 
schizophrenia as a result of a complicated interplay between environmental and genetic 
factors (Bassett, Chow, O’Neill, & Brzustowicz, 2001). It is theorized that problems in 
environmental or genetic domains may negatively influence early neurological 
development, which later can lead to structural abnormalities in the adult brain, including 
the extracellular matrix. These neuroanatomical problems are postulated to result in the 
development of schizophrenia in adolescence or early adulthood (Weinberger, 2010; 
Berretta, 2012; Brown & Patterson, 2012). 
Aloysius Alzheimer (1864-1915) and Franz Nissl (1860-1919) carried out the 
earliest documented biological investigations of schizophrenia in postmortem brain 
samples and were the first to report that there were neurobiological changes in the brains 
donated by individuals with schizophrenia (McKenna, 1997).  
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Alzheimer studied brain samples from individuals who were believed to have 
schizophrenia and also displayed cationic features. After these individuals passed away, 
Alzheimer removed their brains and cut the brain into thin slices. This method allowed 
Alzheimer to study and compare structural differences between brain samples donated by 
individuals with schizophrenia to the non-affected individuals.  
Specifically, Alzheimer discovered that there were differences in the cerebral 
cortex in samples donated by individuals with schizophrenia. The cerebral cortex is 
usually two to four millimeters thick and is the outermost part of the brain. The cerebral 
cortex is involved in many cognitive processes including, thinking, attention, and 
consciousness (Bear, 2001, Kalia, Madhu, & Costa, 2015). 
Most notably, Alzheimer found that in the brain samples recovered from 
individuals diagnosed with schizophrenia, many of the cells that make up the cerebral 
cortex were smaller, had wrinkled membranes, and their nuclei were swollen.  
Like Alzheimer, Nissl also carried out postmortem studies on brain donations 
from individuals with schizophrenia; however, these individuals did not suffer from 
paralysis and Nissl did not see changes in cells from the cerebral cortex, like Alzheimer 
had previously reported. The presence of paralysis was the major difference between the 
groups and it was concluded that heterogeneous symptoms were caused by diverse 
neurobiological abnormalities (Kraepelin, 1971; Akbarian et al., 1996; Galtrey & 
Fawcett, 2007; Benes & Berretta, 2001).  
Although, the first documented accounts of neuronal abnormalities in 
schizophrenia were delineated in the 19th century, it wasn't until the 1950’s that 
pharmacological interventions for individuals with schizophrenia were developed. The 
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first medication engineered to treat schizophrenia was developed in 1951. The drug was 
called Chlorpromazine and it was sold as Thorazine (Kandel, 2013). 
Collectively, the drugs that were produced soon after were termed first-generation 
antipsychotics or typical antipsychotics (Pies, 2005). They were effective in alleviating 
the positive symptoms experienced by individuals with schizophrenia, but had little effect 
on negative symptoms. Unfortunately, individuals taking first-generation antipsychotics 
were prone to experience various adverse side effects (Shiloh, 2006; Ellenbroek, 2012).   
A study of the molecular mechanisms of first-generation antipsychotics in animal 
models revealed that these drugs lowered levels of the neurotransmitter dopamine. This 
observation gave way to the dopamine hypothesis of schizophrenia, which stated that 
elevated levels of dopamine were responsible for the positive symptoms an individual 
with schizophrenia may typically experience (Pies, 2005; Weinberger, 2010).  
Developed in the 1990s, Clozapine was one the first of a new class of anti-
psychotic medications called second-generation antipsychotics or atypical antipsychotics. 
The second-generation antipsychotics are a diverse group of compounds that are 
considered atypical because they do not cause extrapyramidal side effects with the 
severity of the first-generation antipsychotics (Tuunainen, Wahlbeck, Simon, 2002). 
However, second-generation antipsychotics can produce side effects that include life 
threatening metabolic changes (Peluso, Lewis, Barnes, & Jones, 2012; Gautam & Meena, 
2011). 
Although, first-generation and second-generation antipsychotics are used 
worldwide to treat the positive symptoms associated with schizophrenia, these drugs are 
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less effective in the treatment of socio-cognitive deficits and the negative symptoms that 
individuals with schizophrenia experience (Lally & MacCabe, 2015).  
Recent focus in neuroscience research has honed in on a region of the brain, 
known as the amygdala, which when structurally impaired may contribute to the 
manifestation of certain symptoms individuals with schizophrenia experience (Berretta, 
2012; Pantazopoulos, et. al, 2015).  
The amygdala is responsible for certain cognitive functions that are impaired in 
individuals with schizophrenia, specifically, the amygdala enables an individual to 
perform socio-cognitive processes and regulate emotional behavioral responses. Often, 
individuals with schizophrenia show deficits in these domains (Pinkmam, 2015).  
Much of the amygdala’s role in schizophrenia comes from functional imaging 
studies that show altered neuronal activation in several anatomical regions, including the 
amygdala. It is proposed that increased amygdala activity in individuals with 
schizophrenia may be a contributing factor to the individual’s feelings of heightened 
anxiety and paranoia, which ultimately can lead to one’s withdraw from social behavior 
(Phelps and Ledoux, 2005; Pinkmam, 2015).  
More specifically, imaging studies have shown that individuals with 
schizophrenia, compared to non-affected individuals, have increased amygdala activity in 
response to viewing negative affective stimuli and decreased amygdala activation during 
observation of positive stimuli. These imaging studies supported previous subjective 
reports by individuals with schizophrenia who indicated that they experience more 
negative emotions compared to unaffected individuals (Beck & Holmes, 2011; Pankow, 
et al., 2013).  
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The amygdala works with other brain regions to regulate an individual’s attention, 
evaluation, and response to sensory information. Some of the amygdala’s major functions 
are to enable an individual to evaluate their environment, identify potential threats, and 
initiate behavioral responses aimed to protect the individual from harm. This indicates 
that the amygdala not only increases the individual’s probability of survival but also that 
of the species (de Gelder et al., 2014)  
However, hyperactive amygdala activity, as proposed is the case in individuals 
with schizophrenia, can be detrimental. One example of this is that affected individuals 
are prone to sense danger in response to non-threatening stimuli. This can lead to non-
adaptive behavioral responses, such as paranoia, social withdraw or aggression (Bear, 
2001; Pankow, 2013).  
Another, important socio-cognitive tasks that the amygdala facilitates is the 
ability to identify fear (expressed by facial expressions) in other individuals. The 
amygdala’s role in fear assessment is illustrated in the following two experiments 
(Adophs, 2002). 
In the first experimental paradigm, researchers used an electrical current to 
stimulate the amygdalae of patients during brain surgery. When the amygdala was 
stimulated patients often reported feelings of fear and a sense of imminent danger. In the 
second experimental paradigm, researchers studied individuals whose amygdalae were 
damaged by stroke. These individuals were able to identify most facial expressions, but 
not fearful ones (Aggleton, 1993; Adophs, 2002; Gur et al., 2002). 
This is an especially important area of focus because socio-cognitive factors such 
as the ability to accurately ascertain emotions in facial expressions are impaired in 
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individuals with schizophrenia and hinder affected individuals in engaging in goal 
oriented behaviors (Butcher, Mineka, & Hooley, 2007; Clark, Gosselin, & Goghari, 
2013).  
Because the amygdala enables individuals to carry out socio-cognitive functions 
such as attention, decision-making, and execution of behaviors and individuals with 
schizophrenia show impairments in these domains (Sergerie, Chochol, & Armony, 2008) 
the focus of this thesis will be centered on neurons found in the amygdala.  
More specifically, this thesis will focus on GABAergic neurotransmission in the 
amygdala, which has been associated with cognitive impairments in individuals with 
schizophrenia (Wassef, Baker, & Kochan, 2003; Bernstein, 2007, Berretta, 2009; Lally & 
MacCabe, 2015). GABAergic neurotransmission is inhibitory and a lack of inhibition of 
excitatory neurotransmission may explain why the amygdala may be hyperactive in 
response to neutral stimuli (Pankow, 2013). 
Hampered GABAergic neurotransmission was first documented in individuals 
with schizophrenia who had disturbances in gamma-frequency neuronal synchrony 
(Perry, 1979; Uhlhaas & Singer, 2010; Nakazawa, 2012). This type of neural oscillation 
occurs during cognitive processes, which include: attention, memory formation, and 
consciousness. A specific subtype of GABAergic interneurons facilitates gamma-
frequency neuronal synchrony; these neurons express the protein parvalbumin (PV+ 
GABAergic interneurons) (Williams & Boksa, 2010). 
In order for the brain to generate gamma-frequency neuronal synchrony, 
excitatory neurons are inhibited by PV+ GABAergic interneurons (Bartos, Vida, & 
Jonas, 2007). PV+ GABAergic interneurons are impaired in individuals with 
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schizophrenia and are not able to inhibit excitatory neurons (Benes & Berretta, 2001) as a 
result, gamma-frequency neuronal synchrony does not occur.  
The inability of PV+ GABAergic interneurons to effectively inhibit excitatory 
neurons may be caused by problems with the structures that surround PV+ GABAergic 
interneurons. This area is known as the extracellular matrix, which has numerous 
functions which include: providing structural support for neurons and glia, guiding cells 
during neurogenesis, helping to regulate cell-to-cell communication, and regulating 
neuronal plasticity (Pantazopoulos et al., 2010; McRae & Porter, 2012).  
This is significant because the condition of schizophrenia may be predicated on 
disrupted neuronal cell migration during development and neural connectivity issues in 
adulthood (Pantazopoulos et al., 2010; Berretta, 2011; Berretta, Pantazopoulos, Markota, 
Brown, & Batzianouli, 2015). 
A recent postmortem study showed that there were fewer perineuronal nets 
(condensed extracellular matrix structures) surrounding PV+ GABAergic interneurons in 
the amygdala of subjects with schizophrenia compared to control subjects (Pantazopoulos 
et al., 2010; Sah & Lodge, 2013).  
It is important for neurons to be surrounded by perineuronal nets because a 
reduction in perineuronal nets may impair the inhibitory functions of PV+ GABAergic 
interneurons. This may be because perineuronal nets protect neurons from oxidative 
stress and help to maintain sodium and potassium levels inside nerve cells. Therefore, if 
perineuronal nets are missing or not formed correctly, the neuron is left unprotected from 
damage caused by oxidative stress. In addition sodium and potassium imbalances may 
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occur and the neuron’s firing ability may be compromised (Yamaguchi, 2000; Cabungcal 
et al., 2013).   
There is evidence that the protein Otx2 is needed for the formation of nets during 
early postnatal brain development; Otx2 expression coincides with the formation of 
perineuronal nets. Perineuronal net formation around neurons results in the closing of 
neuro-critical periods of development. A reduction in the expression of Otx2 may result 
in fewer or structurally impaired perineuronal nets (Sugiyama, Prochiantz, & Hensch, 
2009).  
 Otx2 belongs to a group of proteins called transcription factors; these proteins are 
able to guide many biological processes, including neuronal development, by activation 
of various genes needed in the given processes. Development is a highly controlled event 
and schizophrenia may be a consequence of impaired neurological development (Dragan 
et al., 2006; Housset et al., 2013). 
Otx2 is a concrete example of a protein that facilitates developmental processes, 
as Otx2 is first active during embryogenesis, but Otx2 reemerges in postnatal periods of 
development. During embryogenesis, Otx2 is needed for the formation of specific brain 
regions and later, in postnatal stages, Otx2 is needed to drive the maturation of PV+ 
GABAergic cells. Once PV+ GABAergic cells mature, perineuronal nets are able to form 
around and stabilize neurons (Soleman, Filippov, Dityatev & Fawcett, 2013). In the 
absence of Otx2, PV+ GABAergic maturation and perineuronal net formation are 
hindered (Beurdeley, 2012).  
Much of Otx2’s role in embryogenesis has been characterized in mice; upon 
deletion of Otx2 mice fail to develop forebrain and midbrain regions. Thus, Otx2 is vital 
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for the survival of the mouse (Li & Joyner, 2001). Otx2 is needed throughout the life of 
the mouse. For instance, in the mouse visual cortex at post-natal day19, before critical 
period onset, little Otx2 protein is evident.  However, during the peak of the visual 
critical period, there is an increase in Otx2 along with the stabilization of PV+ 
GABAergic interneurons (Sugiyama et al., 2009).  
Similarly, in humans, Otx2 is found in several brain regions during development. 
The presence of Otx2 in these areas indicates that Otx2 also has a functional role in 
human neurodevelopment. Furthermore, the absence of Otx2 results in Otocephaly, a 
lethal condition in which one’s jawbone does not develop (Larsen, Lutterodt, Mollgard, 
& Moller, 2010). 
In later postnatal stages of development Otx2 is not produced by PV+ 
GABAergic interneurons despite evidence that Otx2 is needed to maintain mature PV+ 
GABAergic interneurons; therefore, the source of the protein Otx2 that aids in the 
formation of perineuronal nets around PV+ GABAergic interneurons originates 
elsewhere. Otx2 messenger RNA that gives rise to the protein Otx2 is not found in PV+ 
GABAergic interneurons but it is found in the choroid plexus. This indicates that Otx2 
used to maintain mature PV+ GABAergic interneurons might be produced in the choroid 
plexus (Spatazza et al., 2013).  
Taken together with evidence of GABAergic dysfunction in schizophrenia, it 
makes sense to hone our examination to PV+ GABAergic interneurons located in the 
amygdala. We propose that Otx2 protein is made in the choroid plexus, and then 
packaged in vesicles that are transported in the cerebral spinal fluid, through the lateral 
ventricle to the amygdala.  
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Once Otx2 reaches the amygdala it is able to facilitate the formation of 
perineuronal nets, which will form around mature PV+ GABAergic interneurons. This 
process facilitates the proper functioning of PV+ GABAergic interneurons and we 
propose that this mechanism is disrupted in individuals with schizophrenia. 
 
 
 
 
Figure 1. Proposed molecular underpinnings of the condition of schizophrenia 
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produced in the choroid plexsus 
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Chapter II 
 
Research Method 
 
All post mortem tissue used in this project was received from the Harvard Brain 
Tissue Resource Center. Prior to donation, consenting donors fill out the appropriate 
documentation and register with the Harvard Brain Tissue Resource Center, a National 
Institute of Health affiliated brain repository. Brain donations may also be obtained from 
individuals who are registered organ donors. When the donor passes away, the brain 
repository is notified and the process of donation collection begins.  
Brain collection is a tightly regulated process. First, a qualified professional such 
as a mortician or a trained physician removes the donated brain. In attempt to delay 
degradation of the donated brain, the collection is carried out as quickly as possible. 
Next, the donated brain is packaged, placed on ice, and shipped; a specialized courier 
service is used to deliver the brain to the Harvard Brain Tissue Resource Center located 
at Mclean Hospital in Belmont, Massachusetts.  
Once the brain arrives at Mclean Hospital a trained dissectionist will identify and 
cut out designated brain regions. These specific regions have been selected because 
previous scientific investigation has indicated that abnormalities in these areas are 
correlated to various disease states. Disease areas of interest include Parkinson’s disease, 
schizophrenia, bipolar disorder, and Huntington’s disease. 
Upon removal the brain is first cut in half, separating the left and right 
hemispheres. One hemisphere is immediately placed in formalin to be preserved for later 
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scientific study. This will occur after a pathologist confirms the donor’s medical 
diagnosis. The other hemisphere will be dissected, frozen and stored at negative eighty 
degrees Celsius until it is needed for research.  
 
Amygdala preservation by freezing 
For the experiments carried out in this proposal, I used frozen amygdala tissue 
samples and cerebral spinal fluid donations. The amygdala and cerebral spinal fluid 
samples were prepared using different methods. Amygdala tissue samples were frozen 
and cut prior to experimentation, whereas cerebral spinal fluid samples required less 
processing prior to experimentation. A small volume of cerebral spinal fluid was taken 
dried directly onto a microscope slide without prior freezing.  
In general, freezing biological specimens is a harsh process that can damage the 
specimen. To freeze the amygdala without damaging it, the amygdala was submerged in 
a plastic container that contained O.C.T. O.C.T stands for Optimal Cutting Temperature 
compound. It is a viscous liquid that upon freezing will harden around the tissue and will 
protect it from damage. 
 Next, the container with the amygdala floating in O.C.T was submerged into 
liquid nitrogen. Submersion of the amygdala into liquid nitrogen allowed for rapid 
freezing, which is especially important because rapid freezing in O.C.T reduces damage 
to the tissue.  
Next, the frozen amygdala sample, ensheathed by O.C.T., was placed into a 
cryostat for slicing. The cryostat is a cold chamber that houses a very sharp blade that is 
designed to cut biological samples into extremely thin sections. The sample was cut into 
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slices of approximately twenty micrometers in width. This is necessary because when the 
sample is observed with a microscope, light must be able to penetrate through the sample 
to enable detailed observation of micro-anatomical structures. 
 After the amygdala was cut into thin sections, the sections were placed into 
small, plastic containers and standard immunohistochemical (IHC) procedures were 
carried out. Upon completion of the IHC procedure, vesicles that contained Otx2 were 
visible and were counted using computer an assisted light microscope and Stereo 
Investigator software.   
 
IHC to visualize Otx2 in vesicles for quantification 
Before completion of the IHC reaction, prepared amygdala slices were very light 
in appearance; when observed with a light microscope they were almost entirely 
translucent and the vesicles that contain Otx2 could not be seen. In order to visualize the 
vesicles that contained Otx2, a specific antibody was used to detect Otx2 in both the 
amygdala and cerebral spinal fluid samples. Later, a chemical reagent that turned the 
Otx2-antibody complex brown was applied. This rendered the vesicles that contained 
Otx2 visible to count. 
In general, IHC is performed when undetectable, microscopic structures in 
biological samples need to be identified. It is a multi-step technique that uses a series of 
antibodies and an enzymatic reaction to visualize the protein of interest by turning it dark 
brown or black. 
In these IHC experiments, the first step was to utilize an antibody that recognized 
and attached to Otx2. In essence, this antibody was used to locate a vesicle filled with 
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Otx2 within the sample. The first antibody, called the primary antibody, was added to the 
buffer in which the amygdala was floating in and directly onto the slide that contained 
dried cerebral spinal fluid. The same primary antibody was used in both amygdala and 
cerebral spinal fluid IHC procedures; it was purchased from Abcam (Catalog number: 
ab76748). After the primary antibody attached to Otx2, a second antibody was used to 
attach to the primary antibody. Like the primary antibody, the secondary antibody will 
only bind to specific designated structures; in this case it will only bind to the primary 
antibody that attached to Otx2. 
 The secondary antibody was purchased from Vector Laboratories (Catalog 
number: PI-1000). After the secondary antibody attached to the primary antibody, a 
chemical called 3, 3’-diaminobenzidine, commonly abbreviated DAB, and hydrogen 
peroxide were added to the amygdala and cerebral spinal fluid samples. Horseradish 
peroxidase, attached to the secondary antibody, reacted with hydrogen peroxide to alter 
the chemical DAB and turned it brown. Brown DAB could now be used to identify where 
the secondary antibody had attached to the primary antibody. This was the site of Otx2 in 
the sample. 
After the IHC assay was performed on amygdala samples, the sections were 
manually guided onto a glass microscope slide, using a paintbrush. Two amygdala slices 
were placed on each glass microscope slide. Amygdalae vary in size, but approximately 
forty, twenty-micrometer slices were generated from one amygdala.  
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Quantification of vesicles that contain Otx2 in the amygdala 
Vesicles that contained Otx2 were manually counted using a computer assisted 
light microscope and Stereo Investigator software. The software is advantageous because 
it allows the user to mark objects and keep track of objects in the tissue sample. In 
addition, the software estimates the size of any given area traced by the user. This allows 
the user to determine the number of marked objects in a given area and compare the 
number of marked objects between samples per given area size. 
In the amygdala, the following regions were examined for the presence of vesicles 
that contained Otx2: the lateral, basal, accessory basal, medial, central and cortical nuclei. 
The total area of the amygdala and area of each subdivision of the amygdala was 
identified, measured, and recorded.  The number of vesicles that contained Otx2 in a 
given area was counted. 
The following sampling system was developed to accelerate the counting process: 
first, all the vesicles that contained Otx2 were counted in one entire amygdala sample and 
the numbers of vesicles in each region of the amygdala were documented. Next, by trial 
and error, the Stereo Instigator software was programed with the correct parameters that 
generated a sampling system that matched the original count. This included manipulation 
of the size of the sampled area and number of sample sites. 
Step-wise regression analysis was performed to determine if there were 
significant differences in the number of vesicles that contained Otx2 between 
schizophrenic and control groups. This statistical method took in to account other 
variables besides disease diagnosis that may influence the results. These included: the 
individual’s gender, age, and use of antipsychotics. 
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Preparation of cerebral spinal fluid for IHC 
To detect Otx2 in the cerebral spinal fluid samples, a small amount of cerebral 
spinal fluid was removed from a post mortem brain donation. After the dissectionist cut 
the brain in half, separating the two hemispheres, the lateral ventricle was accessible and 
cerebral spinal fluid was collected with a small device designed to vacuum the fluid out 
of the ventricle and into a small tube. Approximately two milliliters of cerebral spinal 
fluid was available for collection. Forty micrometers of cerebral spinal fluid was 
aliquoted onto a slide and allowed to dry, then stained for identification of Otx2 using the 
same IHC protocol used for vesicle visualization in amygdala samples.  
 
Cerebral spinal fluid and ELISA 
  Enzyme-linked immunosorbent assay (ELISA) is a way to measure the 
amount of protein, such as Otx2, within a sample. The principles described above for the 
IHC are the same in the ELISA assay. The ELISA kit was purchased from Cusabio 
(Catalog number: CSB-EL017299HU). In brief, a small amount of cerebral spinal fluid 
was placed into a well where an antibody that binds to Otx2 is attached to the bottom; the 
sample was incubated for one hour. After this incubation step, the well was washed with 
a buffer and the components of the sample not attached to the antibody were washed 
away, immobilizing Otx2 to the bottom of the well. 
Like in the IHC assay, a secondary antibody was added after the primary antibody 
incubation. This antibody also had horseradish peroxidase attached to it; however, a 
different chemical was used to induce a color change that identified Otx2.  3, 3’, 5, 5’-
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Tetramethylbenzidine (TMB) was used and turned Otx2 a blue color and finally, an 
acidic reagent was added that stopped the chemical reaction and turned the sample 
yellow. A spectrophotometer was used to estimate the amount of Otx2 in each sample 
based on the samples color saturation. The lighter yellow samples contained lower levels 
of Otx2.  
A t-test was performed to determine if there were significant decreases in the 
amount of Otx2 in the samples donated by individuals with schizophrenia.  
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Chapter III 
Results 
 
 Experiments carried out for this thesis were based on observation and 
quantification of vesicles that contained the protein Otx2 in post mortem amygdala and 
cerebral spinal fluid samples.  
 
Vesicles in the amygdala contained Otx2 
 In order to visualize Otx2, IHC experiments utilizing DAB were performed. This 
turned vesicles containing Otx2 a dark color. This experimental procedure revealed the 
presence of numerous vesicles that contained Otx2 in amygdala samples donated by 
healthy control subjects (Figure 2) and by individuals with schizophrenia (Figure 3).  
 
 
Figure 2. Vesicles contained Otx2 in samples donated by healthy controls.    
This image was magnified ten times. 
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Figure 3. Vesicles contained Otx2 in samples donated by individuals with schizophrenia. 
This image was magnified ten times. 
 
 
The next step in this project was to cout the number of vesicles that contained 
Otx2. Once all of the samples were counted, the number of vesicles was compared 
between samples donated by individuals with schizophrenia and the control group. 
During this process, several interesting observations were made about the quality, 
quantity and distribution of vesicles that contained Otx2 in samples donated by both 
individuals with and without shizophrenia.  
For example, vesicles filled with Otx2 were concentrated in a specific region of 
the amygdala; the highest concentration of vesicles that contained Otx2 in the amygdala 
was found adjacent to the lateral ventricle. Moreover, the density of vesicles that 
contained Otx2 decreased moving away from the ventricle and into the tissue. This 
observation was made in amygdala samples donated by both healthy controls (Figure 4) 
and by individuals with schizophrenia (Figure 5). 
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Figure 4. Vesicles near the lateral ventricle in healthy controls.  
This image was magnified two and a half times. 
 
 
 
Figure 5. Vesicles near the lateral ventricle in individuals with schizophrenia.  
This image was magnified two and a half times. 
 
 
 
 Furermore, vesicles containing Otx2 were found in the lateral ventricle in 
amygdala samples donated by the control group (Figure 6) and in samples from 
individuals with schizophrenia (Figure 7). 
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Figure 6. Vesicles inside the ventricle in donated healthy control samples. 
This image was magnified forty times. 
 
 
 
 
Figure 7. Vesicles inside the ventricle in donated schizophrenia samples. 
This image was magnified forty times. 
 
 
 In addition, vesicles that contained Otx2 were oserved to be heterogeneous with 
respect to color and size. In samples donated by healthy controls and by individuals with 
schizophrenia, vesicles ranged from light gray to black (Figure 8 and Figure 9) and also 
showed differnces in size (Figure10 and Figure 11).  
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Figure 8. Light and dark vesicles in samples donated by healthy controls.  
This image was magnified twenty times. 
  
 
 
 
Figure 9. Light and dark vesicles in samples donated by individuals with schizophrenia. 
This image was magnified twenty times. 
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Figure 10. Vesicles varied in size in samples donated by healthy controls.  
This image was magnified twenty times. 
 
 
 
 
Figure 11. Vesicles varied in size in samples donated by individuals with schizophrenia. 
This image was magnified twenty times. 
 
 
 
 
 
 
 
 
 
 
Finally, a subset of vesicles in the amygdala and lateral ventricle appeared to be 
hollow; it appeared that an outline of a vesicle was present, however, it was a translucent 
structure. This was observed in samples donated by healthy control subjects (Figure 12) 
and in samples donated by individuals with schizophenia (Figure 13). 
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Figure 12. Hollow vesicles in samples donated by healthy controls.  
This image was magnified twenty times. 
 
 
 
 
 
 
 
 
 
Figure 13. Hollow vesicles in samples donated by individuals with schizophrenia.  
This image was magnified twenty times. 
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Statistical Analysis 
  Step-wise regression analysis determined that there was not a significant 
difference between the numbers of vesicles found in samples donated by individuals with 
schizophrenia compared to the healthy control groups (p-value <0.05). 
 
Vesicles in cerebral spinal fluid samples contained Otx2 
 In addition to the amygdala, vesicles that contained Otx2 were detected in 
samples of cerebral spinal fluid (Figure 14). In the first set of experiments, in addition to 
vesicles, cells that contained Otx2 were also detected in the cerebral spinal fluid samples. 
These cells also contained Otx2. The presence of vesicles that contain Otx2 in the 
cerebral spinal fluid was a novel finding. 
 
 
Figure 14. Vesicles and cells contained Otx2 in cerebral spinal fluid samples.  
This image was magnified twenty times.  
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 Cells that contained Otx2 in cerebral spinal fluid samples were presumed to be a 
post mortem artifact. This thesis focused on vesicles that contained Otx2; therefore, 
vesicles were isolated from the cells using centrifugation.  
 
 
 
Figure 15. Vesicles in cerebral spinal fluid samples after cells were removed.  
This image was magnified twenty times. 
 
 
 Experiments performed on cerebral spinal fluid revealed approximately five 
vesicles that contained Otx2 were present per forty microliters of cerebral spinal fluid. 
An ELISA assay performed on cerebral spinal fluid samples revealed that there 
was a significant decrease in the concentration of Otx2 in samples donated by individuals 
previously diagnosed with schizophrenia compared to samples donated by healthy control 
individuals (p-value > 0.05)(Table 1 & 2, & 16).  
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Two-sample T for Scizophrenia_Otx2 (ng/ml) vs Control_Otx2 (ng/ml) 
 
                                      
Difference = mu (Scizophrenia_Otx2 (ng/ml)) - mu (Control_Otx2 (ng/ml)) 
 
Estimate for difference:  -150.0 
 
95% CI for difference:  (-217.3, -82.6) 
 
T-Test of difference = 0 (vs not =): T-Value = -4.62 P-Value = 0.000 DF = 22 
 
Table 1. Summary of paired t-test results from comparison of vesicle number between 
samples donated by individuals with schizophrenia and healthy controls. 
 
 
 
 
Number of 
samples 
Mean amount of 
Otx2 (ng/ml) 
Standard 
Deviation Minimum Maximum 
Control 14 307.7 86 183.4 456.3 
Schizophrenia  11 157.7 76.1 72.9 270.6 
 
Table 2. Descriptive statistics 
 
 
 
 
 
Figure 16. Decrease in Otx2 levels in individuals with schizophrenia 
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Chapter IV 
 
Discussion 
 
 
 
Schizophrenia is a chronic and debilitating neuropsychiatric condition that has 
likely affected individuals throughout history (Bark, Varadi, & Sorrentino, 2008; 
Weinberger, 2010). Currently, it is estimated that 1 to 3% of the population worldwide is 
affected with schizophrenia (DSM-5, 2013).  
Accurate diagnosis of schizophrenia can be difficult to ascertain because, in large 
part, clinicians make diagnoses based on an individual’s subjective description of their 
symptoms (Jablensky, 2010). At this time objective biological tests to identify 
schizophrenia are not available. In theory such tests would give a doctor the ability to 
diagnose an individual with schizophrenia based on objective biological criteria. 
 Ideally, biological testing, in corroboration with traditional diagnostic methods for 
identifying schizophrenia would result in faster and more accurate disease diagnosis 
(Hayes, Robinson, Muller, & Wang, 2009).  
Improvements in disease diagnosis are important because individuals with 
schizophrenia, when diagnosed earlier, tend to respond better to treatment. McGlasshan 
argues that it would be ideal to identify individuals in the prodromal phase of 
schizophrenia and begin early treatment interventions. This strategy is predicted to result 
in the best clinical outcomes for affected individuals (McGlasshan, 2005; Schultz, 2007; 
Lake, 2012). 
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The first step in the development of a biological test to screen for schizophrenia is 
to elucidate the molecular underpinnings of the condition. With this in mind, the focus of 
this thesis was on a specific protein called Otx2 and its role in the pathophysiology of 
schizophrenia. The main hypothesis tested in experiments conducted for this thesis work 
was that individuals with schizophrenia would have lower levels of the protein Otx2 
compared to healthy control subjects.  
 This was predicted because Otx2 is required for the development and 
maintenance of PV+ GABAergic interneurons and this class of neurons has functional 
deficits in individuals with schizophrenia (Bartos, Vida, & Jonas, 2007; Berretta, 2012; 
Cabungcal et al, 2013). It may be that a paucity of Otx2 is in part responsible for these 
functional deficits. 
 Furthermore, not only is Otx2 required for the initial development of healthy PV+ 
GABAergic interneurons, but it is also involved in the stabilization of mature PV+ 
GABAergic circuits (Beurdeley, 2012). Mature PV+ GABAergic interneurons are 
ensheathed by perineuronal nets and it has been sown that Otx2 is needed to maintain the 
structural integrity of these nets. Without stable nets, PV+ GABAergic interneurons are 
susceptible to damage (Benes & Berretta, 2001; Cabungcal, 2012).  
 Otx2’s precise role in neuronal development and circuitry stabilization processes 
has not been fully elucidated. Interestingly, mature PV+ GABAergic interneurons do not 
synthesize Otx2 despite their need for it. It appears that Otx2 is transported from another 
site; evidence from mouse models indicates that cells located in the choroid plexus 
produce Otx2 and PV+ GABAergic interneurons in the amygdala utilize choroid plexus 
derived Otx2 (Beurdeley et al., 2012; Spatazza et al., 2013). 
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 Furthermore, experiments in mouse models showed that when Otx2 production 
was disrupted in the choroid plexus, PV+ GABAergic interneurons in the amygdala 
malfunctioned (Beurdeley, 2012). 
 In experiments carried out for this thesis work, Otx2 was found in cells in cerebral 
spinal fluid samples. It is possible that these cells were derived from the choroid plexus 
because the choroid plexus has been shown to shed cells into the cerebral spinal fluid (de 
Reuck & Vanderdockt, 1986).  
This finding is supported by mouse model evidence that Otx2 is produced in the 
choroid plexus. However, future experiments would need to be carried out to positively 
determine that these cells originate in the choroid plexus. Post-mortem cerebral spinal 
fluid may contain other cell types such as inflammatory cells (Morris, Harrison & 
Telford, 2012).  
More definitive evidence that Otx2 is produced in the choroid plexus was recently 
seen in human postmortem samples in our laboratory. Otx2 mRNA, the precursor for 
protein Otx2, was found in the choroid plexus and importantly, Otx2 precursor mRNA 
was not found in the amygdala (Pantazopoulos et al., Manuscript in Preparation). This 
finding also supports the mouse model data, which indicates that neurons in the amygdala 
utilize Otx2 derived from the choroid plexus (Beurdeley et al., 2012).   
It has not been established how Otx2 travels from the choroid plexus to the 
amygdala. Our finding of vesicles filled with Otx2 in the cerebral spinal fluid is a novel 
finding that may explain how Otx2 arrives in the amygdala from its site of synthesis in 
the choroid plexus (Beurdeley et al., 2012).    
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It is known that cells communicate with one another using various types of 
vesicles that contain signaling molecules. Currently, research has categorized several 
types of extracellular vesicles. These include: exosomes, micro-vesicles, ectosomes, and 
large oncosomes (Nakano, Garnier, & Rak, 2015) 
 In essence, vesicle mediated extracellular communication occurs when a specific 
cell types generates a molecule, such as Otx2, packages the molecule into a vesicle, and 
releases the vesicle out of the cell. The vesicle can travel through blood, cerebral spinal 
fluid, or interstitial fluid to its target cell. The advantage of this packaging system is that 
vesicles are stable structures and resistant to degradation, thus they can travel relatively 
long distances (Gyorgy, et al., 2011)  
Because we identified Otx2 in the choroid plexus, in vesicles in the cerebral 
spinal fluid, and concentrated in the amygdala near the lateral ventricle, we believe that 
the protein Otx2 is synthesized in the choroid plexus, packaged into extracellular 
vesicles, and released into the cerebral spinal fluid.  After release into the cerebral spinal 
fluid, vesicles travel through the cerebral spinal fluid until they reach the amygdala. Once 
the vesicles enter the amygdala they release molecules of Otx2 that bind to perineuronal 
nets surrounding PV+ GABAergic interneurons. 
We hypothesized that amygdala samples from individuals with schizophrenia 
would have fewer vesicles filled with Otx2 compared to samples from healthy control 
individuals. In individuals with schizophrenia a decrease in the amount of vesicles filled 
with Otx2 could result in a deficit in the amount of Otx2 available for perineuronal nets 
and PV+ GABAergic interneurons. A deficit in available Otx2 may result in impaired 
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perineuronal nets, which could lead to a disruption in PV+ GABAergic interneuron 
function as seen in schizophrenia. 
However, quantification and comparison of vesicle number between samples from 
individuals with and without schizophrenia revealed that there was not a significant 
difference in the number of vesicle between the two groups. 
However, during the process of vesicle quantification, it was observed that 
vesicles that contained Otx2 were heterogeneous in size and color. This indicated that 
vesicles did not contain the same amount of Otx2.  Therefore, the amount of Otx2 protein 
in vesicles was measured using an enzyme linked immunosorbent assay (ELISA).  
 ELISA assays are considered to be relatively rapid procedures, often used in 
clinical settings to screen for various diseases such as Lyme disease, rheumatoid arthritis, 
and West Nile virus (Lequin, 2005). If the molecular underpinnings of schizophrenia 
were elucidated it may one day be feasible to use an ELISA assay to detect the condition 
of schizophrenia in symptomatic individuals.   
ELISA experiments carried out for this thesis project showed a decrease in the 
amount Otx2 in postmortem samples donated by individuals with schizophrenia. This 
indicates that although the number of vesicles that carry Otx2 is the same between 
samples donated by individuals with schizophrenia and healthy control subjects, the 
quantity of Otx2 protein inside the vesicle may be decreased in samples donated by 
individuals with schizophrenia.  
In this case the hypothesis that a decrease in Otx2 contributes to the 
pathophysiology of schizophrenia by disruption in GABAergic transmission is supported 
by the ELISA findings. Optimistically, this indicates that a potential ELISA based 
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screening assay for schizophrenia could be developed based on measurement of Otx2 
concentration in cerebral spinal fluid samples. 
Future experimental directions should test additional cerebral spinal fluid samples 
to confirm these reported preliminary findings. In addition, ELISA tests for Otx2 in blood 
serum samples should be carried out because in a clinical setting a blood test is a less 
invasive procedure compared to a spinal tap. 
In conclusion, although we hypothesized that there would be fewer vesicles that 
contained Otx2 in postmortem amygdala samples donated by individuals diagnosed with 
schizophrenia; this post mortem study did not support this hypothesis. However, when 
vesicles that contained Otx2 in the amygdala were counted it was observed that the 
vesicles were heterogeneous with respect to color and size. This observation indicated 
that there could be differences in the amount of Otx2 contained in each vesicle.  
Therefore, an ELISA assay was performed and revealed that average Otx2 levels 
in cerebral spinal fluid samples were decreased in post mortem samples donated by 
individuals with schizophrenia. Ideally, in the future, it will be possible to identify 
individuals with schizophrenia by their unique genetic make-up and drugs tailored to 
those unique genetic characteristics will be developed. The consideration of Otx2 as a 
potential biomarker for the condition of schizophrenia is a preliminary step in this 
endeavor. 
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